Liver-chip validation: the evidence and investment gate for a NAM
This white paper treats liver-chip validation as an investment in a specific development decision, not a blanket endorsement of alternative testing platforms. Regulatory terminology and retrospective liver-chip research provide context for a more disciplined validation question. The historical benchmark included 870 chips and 27 small molecules, but its classification results cannot be assumed to predict patient outcomes or a new program’s prospective performance. A transparent hypothetical model compares the cost of validating an additional liver-toxicity screen against expected error costs and potential delay. Under its stated assumptions, a longer gate can reverse the modeled economic benefit. The practical recommendation is to define intended use, pre-agree validation thresholds, test transferability, document inconclusive results and identify what management will do if the evidence is favorable, uncertain or negative. No regulatory qualification or patient benefit is implied.